HEMOSTEMIX ANNOUNCES 91st PATENT ISSUED and FINANCING UPDATEJanuary 7, 2020
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE U.S.
CALGARY, Alberta – January 7, 2020 – Hemostemix Inc. (“HEM,” “Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF), is pleased to announce that it was issued its 91st patent for the generation of NCP-01 from peripheral blood. The patent, Production from Blood of Cells of Neural Lineage, was issued by Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Netherlands, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.
“ACP-01 has been studied and trialed, with reports published concerning patients suffering from angina, peripheral arterial disease, critical limb ischemia, ischemic and dilated cardiomyopathy,” said Thomas Smeenk, President. NCP-01 has been the subject of two animal studies: an induced retina injury model and an induced stroke model; In the stoke model, NCP-01 cells were injected in the cisterna magna, to reach the brain via the cerebrospinal fluid; histological examination of the rats’ brains was completed after 28 days, which demonstrated the cells homed to damaged areas and engrafted only in regions immediately surrounding these areas; In vitro experiments performed in parallel with the animal study demonstrated that NCPs secrete neurotrophic growth factors such as BDNF (Brain Derived Neurotrophic Factor), GDNF (Glial Derived Neurotrophic Factor) and additional stem cell factors,” Smeenk said.
“The impact of these patents to the Company’s value cannot be overstated,” stated Bryson Goodwin, CEO. They firmly establish the Company as the leading peripheral blood sourced autologous stem cell therapy platform,” he said.
NCP-01 will be the subject of an animal study, to re-verify its safety and preliminary efficacy data as generated in two previous studies.
WARRANT EXERCISE ACCELERATION: With respect to the financing announced on January 2, 2020, the Board of Directors passed a resolution to effect an early exercise of the warrants of the unit offering. If, on any 10 consecutive trading days occurring after four months and one day from the Closing Date, the closing sales price of the Common Shares (or the closing bid if no sales were reported on a trading day), as quoted on the Exchange, is greater than or equal to $0.07, the Corporation may provide notice in writing to the holders of the warrants, by issuance of a press release, that the expiry date of the warrants will be accelerated to the 30th day after the date on which the Corporation issued such press release.
ABOUT HEMOSTEMIX INC.
Hemostemix is a publicly traded autologous stem cell therapy company, in business since 2003. A winner of the Economic Forum Technology Pioneer Award, HEM developed, is commercializing ACP-01 and NCP-01, and has used ACP-01 to treat CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other heart conditions addressed by autologous angiogenic precursor stem cells. HEM is the first public company to treat more than 500 no-option end-stage heart disease patients with complete safety and significant efficacy. For example, patient #35, Roger, aged 83, who at age 69 was given six months to live before his treatment November 2, 2005, just celebrated his 14th treatment anniversary.
On October 21, 2019, the Company released a summary: “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup” which noted “…healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients. There were no clinically significant safety issues. Outcomes were maintained for up to 4.5 years…”. The clinical trial is ongoing at 13 clinical sites in Canada and the USA.
HEM owns 91 patents that cover the generation from peripheral blood of ACP-01 and NCP-01, the scaling of production (Automated Cell Therapy System), In Vitro Techniques for use with Stem Cells, a composition of matter – The Creation of a Progenitor Cell – and Regulating Stem Cells. For more information, please visit www.hemostemix.com.
Bryson Goodwin, CEO or Thomas Smeenk, President
Suite 1150, 707 – 7th Avenue S.W.
Calgary, Alberta T2P 3H6
BG: 604-341-1531 or TS: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to fund operations and access the capital required to continue operations, the Company’s stage of development, future clinical trials and results, long-term capital requirements and future developments in the Company’s markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Company’s filing with the Canadian securities regulators, which filings are available at www.sedar.com.
View All News & Media